TriSalus Life Sciences Inc. Stock Price, News & Analysis

TriSalus Life Sciences (Nasdaq: TLSI) has successfully completed its exchange offer and consent solicitation for Preferred Stock, which expired on July 23, 2025. Under the offer terms, preferred shareholders could exchange each share for 3.3 shares of common stock.

The exchange offer saw strong participation with 98.82% of outstanding preferred shares being tendered. Settlement is expected by August 1, 2025. Following sufficient shareholder approval, remaining preferred shares will be automatically converted to common stock at a rate 11.3% lower than the offered rate.

TriSalus Life Sciences (Nasdaq: TLSI) has initiated an exchange offer and consent solicitation for its Series A Convertible Preferred Stock. The company aims to simplify its capital structure by allowing preferred stockholders to exchange their shares for common stock. Each preferred share can be exchanged based on its accrued value divided by $4.00 per share, with up to 11,860,206 common shares available for the exchange.

The company has secured support from holders of approximately 55% of outstanding preferred stock through tender agreements. The offer expires on July 23, 2025. Additionally, TriSalus is seeking consent to amend terms allowing automatic conversion of remaining preferred shares at a 11.3% lower exchange ratio after the offer closes.

TriSalus Life Sciences (NASDAQ: TLSI) has launched the TriNav FLX Infusion System, an enhanced version of their medical device portfolio for treating solid tumors. The new system features improved trackability with twice the length of flexible material at the distal end, enabling better navigation through complex blood vessels. In benchtop testing, TriNav FLX showed a 28% reduction in force during navigation compared to the standard design. The device maintains the same Pressure-Enabled Drug Delivery (PEDD) benefits while offering interventional radiologists more options for patient treatment. Importantly, TriNav FLX is eligible for reimbursement under HCPCS codes C8004 for simulation/mapping and C9797 for treatment procedures, supporting both planning and delivery in radioembolization procedures.

TriSalus Life Sciences (NASDAQ: TLSI) has appointed David B. Patience as its new Chief Financial Officer, effective July 1, 2025. Patience, who previously served as CFO at Accelerate Diagnostics, succeeds James Young, who stepped down for personal reasons on May 30, 2025. During the transition period, Dan Giordano, Vice President of Finance, will serve as acting CFO. Patience brings significant experience in capital markets, strategic product portfolio planning, and M&A analysis from his previous roles at Morgan Stanley's Investment Banking Division, Continental Advisors, and Nuveen Investments. He holds a BS in Business Administration from the University of Colorado and an MBA from the University of Chicago Booth School of Business.

TriSalus Life Sciences (NASDAQ: TLSI) reported strong Q1 2025 financial results, with revenue reaching $9.2 million, marking a 42% year-over-year increase and 11% sequential growth. The company secured $22 million in gross proceeds from a recent private placement. Key highlights include:

The company maintained strong commercial momentum with expanded TriNav® usage in liver embolization and new clinical settings. TriSalus launched TriNav LV™ and TriGuide™ products, expanding PEDD technology applications. The company also received HCPCS code C8004 from CMS, improving reimbursement coverage.

While confirming revenue growth guidance of at least 50% for 2025, TriSalus revised its profitability outlook. Due to strategic investments in sales force expansion and clinical registries, the company no longer expects to achieve adjusted EBITDA or cash flow positivity in 2025. The company projects reaching adjusted EBITDA positivity in H1 2026.

TriSalus Life Sciences (NASDAQ: TLSI), an oncology-focused medical technology company, has scheduled its Q1 2025 financial results conference call for Thursday, May 15, 2025, at 8:00 AM ET. The company, which focuses on improving outcomes for solid tumor patients through innovative delivery technology integrated with standard-of-care therapies, will release its financial results for the quarter ended March 31, 2025, before the call.

Interested participants can register for the phone conference through an online form, after which they will receive dial-in details and a personal PIN via email. The event will be available via webcast on TriSalus' investor relations website, where a replay will also be accessible after the call.

TriSalus Life Sciences has secured a $22.0 million private placement and reported preliminary Q1 2025 revenue of $9.2 million, marking a 42% growth compared to Q1 2024. The revenue was driven entirely by the TriNav® Infusion System.

The private placement, led by Nantahala Capital with participation from Broadfin Holdings and other healthcare-focused investors, will issue 5,500,000 shares at $4.00 per share. Canaccord Genuity serves as the sole placement agent, with closing expected around May 2, 2025.

Additionally, TriSalus is simplifying its capital structure through a planned exchange offer for Series A Convertible Preferred Stock. The company has secured support from holders representing 55% of outstanding Preferred Stock. The exchange offer will allow conversion to common stock at $10.00 per Preferred Share plus accrued dividends, divided by $4.00 per share.

TriSalus Life Sciences (NASDAQ: TLSI) reported strong financial results for Q4 and full-year 2024, with revenues reaching $8.3 million in Q4 and $29.4 million for the full year, showing growth of 44% and 59% respectively versus prior year periods. The company maintained impressive gross margins of 85% in Q4 and 86% for 2024.

Key developments include the launch of TriNav LV Infusion System and TriGuide Guiding Catheter for larger vessels, expanding their addressable market to $375 million. The company completed enrollment in the PERIO-03 Phase 1 trial for pancreatic cancer, with final data expected mid-2025.

For 2025, TriSalus reaffirmed guidance projecting over 50% revenue growth, more than 20% reduction in operating expenses, positive EBITDA, and positive cash flow in H2 2025. The company ended 2024 with $8.5 million in cash and expects sufficient runway throughout 2025.

TriSalus Life Sciences (Nasdaq: TLSI) has secured a new Level II HCPCS code (C8004) from the Centers for Medicare & Medicaid Services for its TriNav® Infusion System, effective April 1, 2025. The code specifically covers simulation angiograms used in pre-treatment mapping for transarterial radioembolization (TARE).

The new code, which carries a Medicare payment rate of $11,341 under APC 5193, will be applicable in hospital outpatient departments and ambulatory surgical centers. This development validates TriNav's role in optimizing Y90 dose delivery and ensures reimbursement clarity for both mapping and treatment procedures.

The pressure-generating catheter system features a one-way valve technology that enhances the accuracy of Y90 dose delivery and improves personalized dosimetry through better prediction capabilities and higher tumor-to-normal tissue ratios.